Combined, methadone and buprenorphine (the active ingredient in Suboxone) have prevented an estimated 24,000 opioid overdose deaths per year in the U.S. since 2018, according to HHS and NIDA evidence reviews. Both work. Both are far more effective than detox alone. The choice between them is not "which is better in general," but "which fits this patient, this access, this insurance, this point in recovery."
This guide is the side-by-side comparison most people get from a doctor's office, but with the math and the access details made explicit. Updated April 2026. Medically reviewed by the RehabPulse editorial team. This is informational only — actual medication decisions should be made with a licensed clinician.
The 60-second answer
A practical summary, before the details:
- Both reduce all-cause mortality in opioid use disorder by about 50% over years of treatment. This is the single most important fact about either medication.
- Methadone is a full opioid agonist. Stronger effect, broader patient fit (especially high-tolerance fentanyl users), but only dispensed at federally regulated opioid treatment programs (OTPs) — often daily, in-person at first.
- Suboxone (buprenorphine + naloxone) is a partial opioid agonist. Ceiling on respiratory depression makes it safer if accidentally combined with other substances. Available by prescription from any waivered doctor, including telehealth in most states. Can be taken at home.
- Cost is comparable when both are insurance-covered ($0–$50 per month copay typical). Without insurance, methadone at an OTP runs $80–$250 a week; Suboxone runs $150–$700 a month plus visit fees.
- The biggest practical difference is access. Methadone requires getting to a clinic. Suboxone requires getting a prescription. Geography decides this for many people.
The wrong question is "which is better." The right question is "which one can I actually access, afford, and stay on for at least 12 months?" The data on outcomes is overwhelming: time on medication is the single biggest predictor of long-term recovery. The medication you can stick with beats the one that looks better on paper.
How each medication works
Methadone is a long-acting full opioid agonist. It occupies the same brain receptors as heroin, oxycodone, and fentanyl, producing similar receptor activation but with a 24-36 hour half-life. That means one daily dose keeps receptors saturated, blocks craving, prevents withdrawal, and (at therapeutic doses of 80-120 mg) blocks the high if someone uses another opioid on top.
The full-agonist nature is what makes methadone effective for high-tolerance patients — someone who was using 5+ pills of M30 fentanyl per day usually cannot get adequate symptom control from Suboxone alone. Methadone has the ceiling to match that tolerance.
Suboxone combines buprenorphine (the active medication) with naloxone (a safety additive). Buprenorphine is a partial agonist — it occupies the same receptors but does not fully activate them. The result is symptom relief and craving suppression with a built-in ceiling on respiratory depression. Take twice the dose, and the effect plateaus rather than escalates. That ceiling is the reason Suboxone is dramatically less risky if combined with alcohol or benzodiazepines, and the reason it can be safely prescribed for at-home use.
The naloxone in Suboxone is mostly inert when taken as directed (under the tongue). Its role is to discourage injection misuse: if someone tries to inject Suboxone, the naloxone activates and precipitates immediate withdrawal. It is a deterrent, not a treatment component.
Effectiveness — what the data actually says
Decades of randomized trials and large observational studies converge on a few clear findings, summarized in the SAMHSA Treatment Improvement Protocol on Medications for Opioid Use Disorder (TIP 63):
- Both medications cut all-cause mortality in opioid use disorder by roughly 50% during treatment. Methadone's effect is slightly larger in highest-severity cases.
- Retention in treatment at 6 months is higher on methadone (60-75%) than Suboxone (40-60%), largely because methadone's stronger agonist effect handles high-tolerance patients better. For low-to-moderate tolerance, the gap closes.
- Illicit opioid use drops 60-90% on both medications versus pre-treatment baseline.
- Detox-only programs (no MAT) have 80-90% relapse rates at 6 months. The data here is unambiguous and has been for two decades. Counterintuitive but well documented: a 7-day detox followed by no medication is statistically worse than no detox at all, because tolerance drops and overdose risk on relapse spikes.
What the data does not show: a clear winner. Most studies put methadone slightly ahead on retention and Suboxone slightly ahead on safety profile, with the gap small enough that patient fit matters more than which medication.
Cost and access — the real-world barrier
For insured patients in 2026:
- Suboxone with insurance: generic buprenorphine/naloxone is on most formularies. Monthly copay typically $0-$50. Office visits with a waivered doctor run $20-$60 copay or free at federally qualified health centers.
- Methadone with insurance: OTP services are covered by most state Medicaid plans, Medicare, and commercial insurance (especially after the 2022 federal expansion of coverage). Out-of-pocket cost is often $0-$10 per visit at federally funded clinics.
Without insurance:
- Suboxone: Generic buprenorphine/naloxone runs $150-$300/month at retail pharmacies. Doctor visits add $80-$200 per visit (every 1-4 weeks typically). Telehealth services like Bicycle Health, Ophelia, and Workit Health offer flat monthly subscriptions in the $200-$400 range that include both the medication and visits.
- Methadone: Cash-pay OTPs charge $80-$250 per week. Sliding-scale OTPs exist; the SAMHSA opioid treatment program directory is the right starting point.
Geography is where this gets real. Suboxone can be prescribed by any doctor who completes an 8-hour training (the X-waiver was eliminated in 2023, removing the prior 30-100 patient limit). Telehealth options cover most U.S. states. Methadone, by federal law, must be dispensed in-person at a licensed OTP. There are roughly 1,900 OTPs nationwide, concentrated in cities. Picture a person living 80 miles from the nearest methadone clinic, working a job that does not flex around clinic hours — for them, Suboxone is the only realistic option, regardless of which medication the data prefers.
For an end-to-end view of insurance and out-of-pocket math, our how much does rehab cost guide covers the broader picture.
Side effects and risks
Both medications share a similar side-effect profile because both are opioids: constipation (almost universal), drowsiness in the first 1-2 weeks, dry mouth, mild weight gain, decreased libido in some patients, and slight QT-interval prolongation on EKG (more pronounced with methadone).
Methadone-specific concerns: QT prolongation at higher doses requires periodic EKG monitoring in most clinics. Methadone overdose is a real risk during the induction phase (first 2 weeks), which is why daily in-person dosing is required initially. Once a patient is stable, "take-homes" of 1-30 days can be earned.
Suboxone-specific concerns: precipitated withdrawal during induction, especially for fentanyl users (the 2025 micro-induction protocol largely solves this, but it requires a clinician who knows the method). Mild risk of dental enamel damage with long-term sublingual use, mitigated by rinsing with water after dissolution. The naloxone component can trigger headaches in a minority of patients.
Combined with alcohol or benzodiazepines, methadone is significantly more dangerous than Suboxone — the ceiling effect of buprenorphine is the main reason. For patients with co-occurring alcohol use disorder or benzodiazepine prescriptions, Suboxone is usually the safer first choice.
Who Suboxone is the better fit for
Imagine a 38-year-old with a 2-year history of oxycodone use, employed full-time, with a $30 insurance copay and a primary care doctor who has waiver training. Sending him to a methadone clinic for daily 6 a.m. dosing would likely cost him his job. Suboxone makes obvious sense: monthly visit, prescription, $30 copay, no clinic schedule.
Suboxone tends to fit best for:
- Moderate-tolerance patients — daily use of pharmaceutical opioids, mild-to-moderate heroin use, or shorter-term fentanyl exposure
- Patients with stable housing and employment who would lose ground from daily clinic visits
- Rural or suburban patients without a nearby OTP
- Patients with co-occurring alcohol or benzodiazepine use (safer combined profile)
- Patients who want eventual taper — Suboxone tapers are generally smoother than methadone tapers, though both can be done
The downside: if symptom control is inadequate at the maximum recommended dose (24 mg buprenorphine), the patient needs to switch to methadone rather than supplement with illicit opioids.
Who methadone is the better fit for
Picture this: a 45-year-old with a 12-year history of high-dose fentanyl use, two prior failed Suboxone inductions due to inadequate symptom control, living in a city with a methadone clinic on the bus line. Methadone is almost certainly the right answer: the agonist strength matches the tolerance, the daily structure provides accountability, and the OTP usually includes free counseling and case management.
Methadone tends to fit best for:
- High-tolerance patients — heavy daily fentanyl, long-term heroin use, multi-year opioid dependence
- Patients who have tried Suboxone and had inadequate symptom control or repeated relapses
- Patients in chaotic life situations where the structure of daily clinic attendance is a feature, not a bug
- Patients near an OTP with reliable transportation
- Patients with chronic pain alongside opioid use disorder — methadone is also analgesic, where buprenorphine's pain control is more limited
The downside: the daily clinic requirement is a significant time commitment for the first 6-24 months. Take-home privileges expand over time based on clinical stability and clean drug screens.
For tracking daily progress on either medication, a day-by-day sobriety tracker helps surface patterns. For families navigating a loved one's fentanyl use specifically, the fentanyl withdrawal symptoms guide explains why MAT is non-optional for that substance in particular.
Other resources on RehabPulse worth pinning:
- Insurance and rehab coverage guide
- Find treatment by state
- Resources library
- DAST-10 drug use self-assessment
- Alcohol withdrawal timeline
Frequently asked questions
Which is more effective, Suboxone or methadone? Both reduce all-cause mortality in opioid use disorder by about 50% during treatment. Methadone has slightly higher retention rates in studies (60-75% at 6 months vs 40-60% for Suboxone), largely because it handles high-tolerance fentanyl users better. For low-to-moderate tolerance, the effectiveness gap closes considerably.
Can you switch from Suboxone to methadone or vice versa? Yes, both directions are routine and clinically established. Suboxone to methadone is straightforward — taper off Suboxone for 24-48 hours, start methadone induction. Methadone to Suboxone is more delicate: methadone must be tapered down to 30-40 mg daily, then a 36-72 hour washout, then careful buprenorphine micro-induction to avoid precipitated withdrawal.
How long do people stay on Suboxone or methadone? The current evidence supports treatment for at least 12 months minimum, with many patients staying on medication for several years or indefinitely. Discontinuation under 12 months is associated with high relapse rates. There is no medical "limit" to how long someone can stay on either medication safely.
Does insurance cover Suboxone and methadone in 2026? Yes. Under the Mental Health Parity and Addiction Equity Act, addiction medications must be covered at parity with other prescriptions. Most ACA marketplace plans, employer plans, Medicaid, Medicare, and VA cover both generic buprenorphine/naloxone and methadone at OTPs. Coverage details vary by plan — call the behavioral health number on your insurance card to confirm copay and any prior authorization requirements.
Is taking Suboxone or methadone "just trading one addiction for another"? No. This is the most common misconception about MAT, and every major medical organization (NIDA, SAMHSA, ASAM, WHO) has rejected it. Addiction involves compulsive use despite harm. Patients on stable MAT doses can drive, work, parent, and live normal lives. Stopping the medication is the action that produces "addiction-like" symptoms — exactly because the underlying brain changes from opioid use disorder are still present. MAT manages a chronic condition, the same way insulin manages diabetes.
